Search
Search Results
##search.searchResults.foundPlural##
-
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1569PDF: 801HTML: 216 -
Guest Editor: G. Castaman AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION Hemophilia and aging
1731PDF: 1453HTML: 254 -
FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients
1066PDF: 625Html: 163 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1223PDF: 416HTML: 98 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2613PDF: 756HTML: 2313 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3383PDF: 1492HTML: 4016 -
I INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS
1171PDF: 488HTML: 329 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1354HTML: 328PDF: 958Suppl. Files: 470 -
The labyrinth of pyrexia of unknown origin: A case of intravascular B cell lymphoma
1805PDF: 697HTML: 2417Untitled: 161Figure 1 a: 167Figure 1 b: 177Fig 1 c: 160Figure 1 d: 206 -
REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE
12412PDF: 1685HTML: 4214Cover letter: 205Figure 1: 213 -
CROCIN PROMOTES APOPTOSIS IN HUMAN EBV-TRANSFORMED B-LYMPHOCYTE VIA INTRINSIC PATHWAY CROCIN PROMOTES APOPTOSIS IN EBV-TRANSFORMED LCL
1308PDF: 505HTML: 207 -
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3268PDF: 1467HTML: 5953Fig1-Ag-Pil: 236Ag-Pil Fig.2: 239 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1422PDF: 829HTML: 3124 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1998PDF: 777HTML: 702 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2065PDF: 847HTML: 261 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3354PDF: 1369HTML: 2676 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1789PDF: 1182HTML: 253 -
VITAMIN D STATUS IN THALASSEMIA MAJOR: AN UPDATE
2756PDF: 1093HTML: 2583 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2564PDF: 853HTML: 8902Efremov 1: 237Efremov 2: 202 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
403PDF: 363Suppl. Files: 52HTML: 22 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4094PDF: 1163HTML: 1971Fig.1: 219Fig. 2: 113Table 1: 207Table2: 225Table 3: 203 -
Pidotimod in paucisymptomatic SARS-CoV2 infected patients Pidotimod in COVID-19
3068PDF: 1887HTML: 982 -
Acquired Sideroblastic Anemia: An exploratory Comparative Statistical Analysis Between Clonal and Non-clonal cases Acquired Sideroblastic Anemia
993PDF: 602HTML: 380 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1409PDF: 778HTML: 946







